Synchroneuron
Newton · Founded 2011
About Synchroneuron
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders. Its lead candidate SNC-102, a sustained-release formulation of acamprosate calcium is being evaluated in phase 2 trials for tardive dyskinesia (TD) and Tourette syndrome (TS) and in phase 1 trials for combat-related posttraumatic stress disorder (cPTSD).
Company Facts
- Founded: 2011
- Legal name: Synchroneuron Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $26.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2014)
- Website: synchroneuron.com
- Phone: 617-538-5688
Canonical: https://fsome.com/organization/synchroneuron-8340695 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.